PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.50
Similar to AXSM's ratio of 1.57. Walter Schloss would see both operating with a similar safety margin.
1.50
Similar ratio to AXSM's 1.51. Walter Schloss might see both running close to industry norms.
1.48
Cash Ratio above 1.5x AXSM's 0.89. David Dodd would confirm if this large cash position offsets potential expansions or acquisitions.
-2327.49
Negative interest coverage while AXSM shows 20.02. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
-27.48
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.